185 related articles for article (PubMed ID: 36159844)
1. SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC.
Hasmim M; Xiao M; Van Moer K; Kumar A; Oniga A; Mittelbronn M; Duhem C; Chammout A; Berchem G; Thiery JP; Volpert M; Hollier B; Noman MZ; Janji B
Front Immunol; 2022; 13():982821. PubMed ID: 36159844
[TBL] [Abstract][Full Text] [Related]
2. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells.
Singh D; Deshmukh RK; Das A
Cell Signal; 2021 Nov; 87():110151. PubMed ID: 34537302
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
5. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
9. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
10. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
[TBL] [Abstract][Full Text] [Related]
12. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
13. A role for EMT in CD73 regulation in breast cancer.
Hasmim M; Berchem G; Janji B
Oncoimmunology; 2022; 11(1):2152636. PubMed ID: 36465484
[TBL] [Abstract][Full Text] [Related]
14. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
Dong B; Ding Y; Huang Q; Guan X
Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
17. Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment.
Gao B; Chen J; Han B; Zhang X; Hao J; Giuliano AE; Cui Y; Cui X
Sci Rep; 2021 Jan; 11(1):2408. PubMed ID: 33510281
[TBL] [Abstract][Full Text] [Related]
18. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
19. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.
Cao L; Bridle KR; Shrestha R; Prithviraj P; Crawford DHG; Jayachandran A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163489
[TBL] [Abstract][Full Text] [Related]
20. Scleraxis regulates Twist1 and Snai1 expression in the epithelial-to-mesenchymal transition.
Al-Hattab DS; Safi HA; Nagalingam RS; Bagchi RA; Stecy MT; Czubryt MP
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H658-H668. PubMed ID: 29906225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
